CN105853430A - Application of composition of piperazine and imidazole based derivatives of Virosaine A in preparation of drugs against red blood cell hypoplastic anemia - Google Patents
Application of composition of piperazine and imidazole based derivatives of Virosaine A in preparation of drugs against red blood cell hypoplastic anemia Download PDFInfo
- Publication number
- CN105853430A CN105853430A CN201610278690.6A CN201610278690A CN105853430A CN 105853430 A CN105853430 A CN 105853430A CN 201610278690 A CN201610278690 A CN 201610278690A CN 105853430 A CN105853430 A CN 105853430A
- Authority
- CN
- China
- Prior art keywords
- anemia
- compositions
- composition
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 210000003743 erythrocyte Anatomy 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 208000032467 Aplastic anaemia Diseases 0.000 title claims abstract description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title abstract description 8
- FSDTUOKRYYZAQY-AEAJCJRFSA-N (1S,6S,8R,9R,12S,15R)-8-hydroxy-5,10-dioxa-11-azapentacyclo[7.6.0.02,6.06,12.011,15]pentadec-2-en-4-one Chemical class O[C@@H]([C@@H]1ON23)C[C@@]45[C@@H]3CC[C@@H]2[C@@H]1C4=CC(=O)O5 FSDTUOKRYYZAQY-AEAJCJRFSA-N 0.000 title abstract description 6
- 229940079593 drug Drugs 0.000 title abstract description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title abstract description 3
- 125000004193 piperazinyl group Chemical group 0.000 title abstract description 3
- 206010021074 Hypoplastic anaemia Diseases 0.000 title abstract 5
- 208000007502 anemia Diseases 0.000 claims description 44
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 20
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 14
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- -1 phosphate amine Chemical class 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 3
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000002607 hemopoietic effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 208000035126 Facies Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 208000035220 Dyserythropoietic Congenital Anemia Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 201000004440 congenital dyserythropoietic anemia Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000010437 erythropoiesis Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000011715 vitamin B12 Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 240000007003 Flueggea virosa Species 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000867909 Securinega Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 239000002027 dichloromethane extract Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 0 CCCN(CCN)CCO[C@](C)(C1(C(CCC2=C3)[C@]4(C)N(CI=CC)[C@@]5(*)CC4)[C@]25OC3=O)[C@]1(C)O Chemical compound CCCN(CCN)CCO[C@](C)(C1(C(CCC2=C3)[C@]4(C)N(CI=CC)[C@@]5(*)CC4)[C@]25OC3=O)[C@]1(C)O 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
- 206010015287 Erythropenia Diseases 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000036581 Haemorrhagic anaemia Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 206010027540 Microcytosis Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000009527 Refractory anemia Diseases 0.000 description 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ODJZWVFLHZHURI-UHFFFAOYSA-M [Br-].C(CCC)[P+](CCCC)(CCCC)CCCC.[NH4+].[Br-] Chemical compound [Br-].C(CCC)[P+](CCCC)(CCCC)CCCC.[NH4+].[Br-] ODJZWVFLHZHURI-UHFFFAOYSA-M 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of a composition of piperazine and imidazole based derivatives of Virosaine A in preparation of drugs against red blood cell hypoplastic anemia, relates to the fields of organic synthesis and medicinal chemistry, in particular to the composition, a preparation method and application of the composition in preparation of drugs against red blood cell hypoplastic anemia and discloses a composition and a preparation method. Pharmacological experiments show that the composition has an anti-red blood cell hypoplastic anemia effect and has the value of developing the drugs against red blood cell hypoplastic anemia.
Description
Technical field
The present invention relates to organic synthesis and medicinal chemistry art, be specifically related to compositions, preparation method and use thereof
On the way.
Background technology
Based on different clinical characters, anemia has different classification.As: divide acute and chronic by anemia tempo
Anemia；Divide hyperplastic anemia (as thin in hemolytic anemia, iron deficiency anemia, huge children by bone marrow red system proliferative conditions
Born of the same parents' anemia etc.) and Hypolasia anemia (such as aplastic anemia).
Clinically often from anemia pathogenesis and the classification of the cause of disease:
1. erythropoiesis minimizing property anemia
The anomalous effects erythropoiesis of hematopoietic cell, marrow stromal cell and hemopoietic raw material, can be formed red carefully
Born of the same parents generate minimizing property anemia.
(1) hematopoietic stem/progenitor cells caused by abnormal anemia
1) aplastic anemia (AA) AA is a kind of marrow hematopoiesis function failure disease, with primary and secondary
Hematopoietic stem/progenitor cells infringement relevant.The pathogenesis of parts whole blood cytopenia produces anti-bone with B cell
Myelocyte autoantibody, and then destroy or suppress myeloid element relevant.
2) pure red cell aplasia anemia (PRCA) PRCA refers to that bone marrow erythroid hematopoiesis stem/progenitor cells is subject to
To infringement, and then cause anemia.According to the cause of disease, this disease can be divided into congenital and posteriority two class.Congenital
PRCA i.e. Diamond-Blackfan syndrome, is caused by heredity；Posteriority PRCA include primary, continue
Send out two classes.Having scholar to find in part constitutional PRCA patients serum has self EPO or normoblast antibody.
Secondary cases PRCA mainly has medicine relationship type, (antibacterial and virus, such as piconavirus B to infect relationship type19、
Hepatitis virus etc.), autoimmune disease relationship type, lymphoproliferative disease relationship type is (such as thymoma, pouring
Bar tumor, plasma cell dyscrasia and Lymphocytic leukemia etc.) and acute aplastic crisis etc..
3) to be that ancestral does in a red system of class heritability thin for congenital dyserythropoietic anemia (CDA) CDA
Born of the same parents' optimum clone caused by abnormal, the refractory anemia that is characterized with red system ineffective hematopoiesis and paramophia.According to
Mode of inheritance, this disease can be divided into autosome hidden flight of steps leading to a palace hall genotype and dominant inheritance's type.
4) these disease hematopoietic stem/progenitor cells of hemopoietic system malignant clone disease there occurs the exception of matter, including
Myelodysplastic syndrome and all kinds of hematopoietic system cancer disease such as leukemia etc..The former is because of DH,
High hypertrophy, high apoptosis, hemolysis in situ occurs；The latter's neoplastic hyperplasia, low apoptosis and low differentiation, hemopoietic regulates
Also be affected so that normal mature erythrocytopenia and there is anemia.
(2) hematopoieticmicroenviron-ment caused by abnormal anemia
Hematopoieticmicroenviron-ment includes bone marrow matrix, stromal cell and cytokine.
1) bone marrow matrix and stromal cell impaired Anemia BMN, myelofibrosis, myelosclerosis,
The bone marrow neoplasms of marble extramedullary tumor disease sick, various and various infection or non-infectious osteomyelitis, all
Can be because of damage bone marrow matrix and stromal cell, hematopoieticmicroenviron-ment occurs abnormal and affects hemopoietic.
2) hematopoietic regulators horizontal abnormality Anemia stem cell factor (SCF), interleukin (IL),
Grain-monosystem colony stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF), erythrocyte are raw
Cheng Su (EPO), thrombopoietin (TPO), PDGF (TGF), neoplasm necrosis
The factor (TNF) and interferon (IFN) etc. are respectively provided with positive negative regulation hemoposieis.Renal insufficiency, hepatopathy
Not enough with producing EPO when hypophysis or hypothyroidism etc.；Neoplastic disease or some virus infection can lure
Lead body and produce more hemopoietic negative regulatory factor such as TNF, IFN, inflammatory factor etc., all may result in chronic disease
Property anemia (ACD).
(3) hemopoietic insufficient raw material or Use barriers Anemia
Hemopoietic raw material refers to material necessary to hematopoietic cell proliferation, differentiation, metabolism, as protein, lipid,
Vitamin (folic acid, vitamin B12 etc.), trace element (ferrum, copper, zinc etc.) etc..Any one hemopoietic
Insufficient raw material or Use barriers all may cause erythropoiesis to reduce.
1) folic acid or vitamin B12Lack or Use barriers Anemia is led due to various physiology or pathological factor
Cause body folic acid or absolute or that shortage or Use barriers can cause the relatively megaloblastic anemia of vitamin B12.
2) iron deficiency and ferrum Use barriers anemia this be the most modal anemia.Iron deficiency and ferrum Use barriers
Affecting haemachrome synthesis, having such anemia is called haemachrome resulting anomaly anemia.The erythrocyte shape of such anemia
State diminishes, and central authorities' olistherozone expands, and belongs to microcytic hypochromic anemia.
2. hemolytic anemia (HA)
I.e. hematoclasis too much property anemia.
3. hemorrhagic anemia
Dividing acute and chronic according to speed of losing blood, chronic blood loss anemia often merges iron deficiency anemia.Can be divided into
Go out disorders of blood coagulation (such as idiopathic thrombocytopenic purpura, hemophilia and severe liver disease etc.) make peace non-go out
Disorders of blood coagulation (such as wound, tumor, tuberculosis, bronchiectasis, peptic ulcer, hemorrhoid and gynaecopathia etc.)
Caused two classes.
From natural product, find compound or lead compound and carry out structural modification and obtain its derivant, thus
The potential drug obtaining high-efficiency low-toxicity most has important value.
The compound I that the present invention relates to be one within 2012, deliver (Bing-Xin Zhao et al., 2012.
Virosaines A and B,Two New Birdcage-Shaped Securinega Alkaloids with an
Unprecedented Skeleton from Flueggea virosa.Organic Letters 14(2012)3096–3099)
Compound, we have carried out structural modification to compound I, it is thus achieved that two i.e. compound III of new derivant
With compound IV, and it is prepared for compositions and to said composition anti-erythrocyte with compound III and compound IV
Low property anemia activity is evaluated, and it has anti-erythrocyte low property anemia activity.
Summary of the invention
The invention discloses a new compositions, said composition is made up of compound III and compound IV, should
In compositions, the mass percent of compound III and compound IV is respectively 35% and 65%.
Compositions disclosed by the invention can make pharmaceutically acceptable salt or pharmaceutically acceptable carrier.
It is an object of the invention to provide the present composition new application in pharmaceutical field.
The present invention relates to compositions as the application in preparation treatment erythrocyte low property anemia medicine.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not had
Any restriction of body embodiment, but be defined in the claims.
Detailed description of the invention
The preparation of embodiment 1 compound Virosaine A
The document that the preparation method of compound Virosaine A (I) is delivered with reference to Bing-Xin Zhao et al.
(Bing-Xin Zhao et al.,2012.Virosaines A and B,Two New Birdcage-Shaped
Securinega Alkaloids with an Unprecedented Skeleton from Flueggea virosa.Organic
Letters 14 (2012) 3,096 3099) method.
The synthesis of O-bromoethyl derivant (II) of embodiment 2Virosaine A
Compound I (235mg, 1.00mmol) is dissolved in 20mL benzene, in solution, adds tetrabutyl phosphonium bromide
Ammonium (TBAB) (0.08g), glycol dibromide (3.760g, 20.00mmol) and 50% hydrogen of 5mL
Sodium hydroxide solution.Mixture stirs 8h at 35 degrees Celsius.After 8h, reactant liquor is poured in frozen water, immediately
It is extracted twice with dichloromethane, merges organic phase solution.Then to organic phase solution successively with water and saturated common salt
Water washs 3 times, then is dried with anhydrous sodium sulfate, and last concentrating under reduced pressure is removed solvent and obtained product crude product.Product
Crude product silica gel column chromatography purification (flowing is mutually: petroleum ether/acetone=100:1.0, v/v), collects brown and concentrates
Elution band is also flung to solvent and is i.e. obtained the brown ceramic powder (261mg, 78%) of compound II.
1H NMR(500MHz,DMSO-d6)δ5.91(s,1H),4.07(s,1H),3.81(s,2H),3.59(s,1H),
3.43 (s, 2H), 3.33 (s, 1H), 2.26 (s, 1H), 1.58 (d, J=9.8Hz, 3H), 1.41 (s, 2H).
13C NMR(125MHz,DMSO-d6)δ171.81(s),106.71(s),79.95(s),74.33(s),69.81
(s),66.68(s),44.21(s),35.56(s),33.28(s),25.85(s),21.88(s).
HRMS(ESI)m/z[M+H]+calcd for C14H17BrNO4:342.0341；found 342.0343.
The synthesis of O-(piperazinyl) ethyl derivative (III) of embodiment 3Virosaine A
Compound II (171mg, 0.5mmol) is dissolved in the middle of 20mL acetonitrile, is added thereto to anhydrous carbon
Acid potassium (690mg, 5.0mmol), potassium iodide (168mg, 1.0mmol) and Piperazine anhydrous (3446mg,
40mmol), mixture is heated to reflux 3h.Reactant liquor is poured in frozen water after terminating by reaction, uses equivalent dichloro
Methane extracts 2 times, merges organic facies.Organic facies after merging with water and saturated aqueous common salt washing successively, then
Being dried with anhydrous sodium sulfate, concentrating under reduced pressure is removed solvent and is obtained product crude product.Product crude product silica gel column chromatography is pure
Change (flowing is mutually: petroleum ether/acetone=100:1.0, v/v), collect brown and concentrate elution band and fling to solvent i.e.
Obtain the Light brown solid (123.2mg, 71%) of compound III.
1H NMR(500MHz,DMSO-d6)δ5.90(s,1H),4.04(s,1H),3.59(s,1H),3.50(s,
2H), 3.40 (d, J=65.9Hz, 1H), 2.64 (s, 4H), 2.54 (s, 2H), 2.31 (s, 4H), 2.22 (s, 1H),
1.62(s,2H),1.56(s,1H),1.43(s,2H),0.97(s,1H).
13C NMR(125MHz,DMSO-d6)δ171.84(s),106.72(s),79.94(s),74.33(s),
66.72 (d, J=9.2Hz), 54.45 (s), 54.16 (s), 45.25 (s), 44.20 (s), 35.56 (s), 25.86 (s),
21.87(s).
HRMS(ESI):m/z[M+H]+calcd for C18H26N3O4:348.1923；found:348.1927.
The synthesis of O-(imidazole radicals) ethyl derivative (IV) of embodiment 4 Virosaine A
Compound II (171mg, 0.5mmol) is dissolved in the middle of 25mL acetonitrile, is added thereto to anhydrous carbon
Acid potassium (690mg, 5.0mmol), potassium iodide (252mg, 1.5mmol) and imidazoles (870mg, 10mmol),
Mixture is heated to reflux 2h.Reactant liquor is poured in 25mL frozen water after terminating by reaction, uses equivalent dichloromethane
Extract 3 times, merge organic facies.Organic facies after merging with water and saturated aqueous common salt washing successively, then use nothing
Aqueous sodium persulfate is dried, and concentrating under reduced pressure is removed solvent and obtained product crude product.Product crude product silica gel column chromatography purify (stream
Dynamic it is mutually: petroleum ether/acetone=100:0.3, v/v), collect brown and concentrate elution band and fling to solvent and i.e. changed
The Light brown solid (144.1mg, 71%) of compound IV.
1H NMR(500MHz,DMSO-d6)δ7.86(s,1H),7.12(s,1H),6.71(s,1H),5.99(s,
1H), 4.09 (s, 1H), 3.89 (d, J=16.4Hz, 2H), 3.80 (s, 2H), 3.58 (s, 1H), 3.35 (s, 1H),
2.31(s,1H),1.68(s,1H),1.58(s,2H),1.44(s,2H).
13C NMR(125MHz,DMSO-d6)13C NMR(125MHz,Common NMR Solvents)δ
171.82(s),139.64(s),128.67(s),119.31(s),106.70(s),79.92(s),74.31(s),67.61(s),
66.66(s),44.20(s),43.75(s),35.52(s),25.85(s),21.86(s).
HRMS(ESI):m/z[M+H]+calcd for C17H20N3O4:330.1454；found:330.1458.
Embodiment 5 compositions anti-erythrocyte low property anemia is tested
One, the compositions therapeutical effect to post hemorrhagic mice
ICR mice 30, ♀ ♂ half and half, it is divided into 5 groups (n=10).In addition to normal saline group, other group
Every mice, from orbital vein blood-letting 0.5ml, takes blood again and surveys whole index of respectively organizing, then continuous gavage after 24h
Blood-letting every day 0.5ml after being administered 1 week and being administered, after last is administered 1h, takes blood F-800 from orbital venous plexus
Full whole bliid platelet analyzer carries out red blood cell count(RBC) (1012/L)。
The preparation of compositions: powder and the grinding of the 35mg compound III of 200 mesh nets will be crossed after grinding
The powder of the 65mg compound IV of rear mistake 200 mesh net loads in tubule with cover and mixes with turbine stirring instrument
I.e. obtain 100mg compositions, during use, obtain the solution of compositions by the compositions of this 100mg of water dissolution.
Table 1 compositions is to because of caused oligocythemic therapeutical effect of losing blood
Compare with model group: * p < 0.05
Result shows, blood-letting mice, after taking compositions and treating 7 days, is compared with model group, and its erythrocyte shows
Write higher than model group, close to normal saline group.And compound III and compound IV acts on without this.
Two, compositions causes oligocythemic therapeutical effect to cyclophosphamide
Preventive and therapeutic effect ICR mice 50 to the damage of mouse bone marrow cells hemopoietic function, ♀ ♂ dual-purpose, it is divided into 5
Group (n=10), i.e. normal saline group, modeling group, compositions 1.2mg/kg group, compound III 1.2mg/kg
Group and compound IV 1.2mg/kg group, oral administration, every day 1 time.Within 0th, 5,10th, remove normal saline group
Outward, other respectively organizes mice lumbar injection cycli phosphate amine 80mg/kg respectively, then proceedes to be administered 3 days.In last
1h after administration, takes blood from orbital venous plexus, surveys RBC number (1012/L)。
The impact erythrocytic on caused by cyclophosphamide of table 2 compositions
Compare with model group: * * p < 0.01
Result shows, compares with normal saline group, and cycli phosphate amine can make mouse bone marrow cells damage, and causes peripheral blood thin
Born of the same parents decline, and compositions group compares with model group, can substantially resist cycli phosphate amine induced mice red blood cell decreased.And
Compound III and compound IV acts on without this.
Three, compositions is to therapeutical effect oligocythemic caused by benzene
Impact on Induced Aplastic Anemia Mice: Kunming mouse 50, ♀ ♂ dual-purpose, it is divided into 5 groups
(n=10), in addition to normal saline group, other organizes mouse subcutaneous injection benzene 0.5ml/kg, continuous 12 days, modeling
The same day, oral administration simultaneously, every day 1 time, totally 18 days, last be administered after 1h, orbital venous plexus takes blood,
Survey erythrocyte.
Table 3 compositions is to therapeutical effect oligocythemic caused by benzene
Compare with model group: * * p < 0.01
Result shows, compositions group compares with model group, can substantially resist Induced Aplastic Anemia Mice caused by benzene
Erythrocytic decline.And compound III and compound IV acts on without this.
Conclusion: compositions can significantly raise erythrocyte, can be used to the medicine of preparation treatment anemia.And chemical combination
Thing III and compound IV can not significantly raise erythrocyte, it is impossible to is used for preparing the medicine for the treatment of anemia.
The preparation of embodiment 6 composition tablet involved in the present invention
Taking 2 grams of compositionss, the customary adjuvant 18 grams of tablet is prepared in addition, and mixing, conventional tablet presses makes 100
Sheet.
The preparation of embodiment 7 composition capsule involved in the present invention
Taking 2 grams of compositionss, the customary adjuvant such as starch 18 grams of capsule is prepared in addition, mixing, encapsulated system
Become 100.
Claims (7)
1. a compositions, is characterized by that said composition is made up of, in said composition compound III and compound IV
The mass percent of compound III and compound IV is respectively 35% and 65%,
2. the preparation method of compositions as claimed in claim 1, is characterized by: by powder and the change of compound III
The powder of compound IV is sufficiently mixed according to mass percent respectively 35% and 65%.
3. a compositions as claimed in claim 1 application in treatment erythrocyte low property anemia medicine.
4. the compositions as claimed in claim 3 application in treatment erythrocyte low property anemia medicine, its feature
For: described erythrocyte low property anemia is caused by losing blood.
5. the compositions as claimed in claim 3 application in treatment erythrocyte low property anemia medicine, its feature
For: described erythrocyte low property anemia is low by the erythrocyte caused by chemical substance.
6. the compositions as claimed in claim 5 application in treatment erythrocyte low property anemia medicine, its feature
For: described chemical substance is benzene, and described erythrocyte low property anemia is by the aplastic anemia caused by benzene.
7. the compositions as claimed in claim 5 application in treatment erythrocyte low property anemia medicine, its feature
For: described chemical substance is cycli phosphate amine, and described erythrocyte low property anemia is by erythrocyte caused by cycli phosphate amine
Decline.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610278690.6A CN105853430A (en) | 2016-04-28 | 2016-04-28 | Application of composition of piperazine and imidazole based derivatives of Virosaine A in preparation of drugs against red blood cell hypoplastic anemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610278690.6A CN105853430A (en) | 2016-04-28 | 2016-04-28 | Application of composition of piperazine and imidazole based derivatives of Virosaine A in preparation of drugs against red blood cell hypoplastic anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105853430A true CN105853430A (en) | 2016-08-17 |
Family
ID=56629836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610278690.6A Pending CN105853430A (en) | 2016-04-28 | 2016-04-28 | Application of composition of piperazine and imidazole based derivatives of Virosaine A in preparation of drugs against red blood cell hypoplastic anemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105853430A (en) |
-
2016
- 2016-04-28 CN CN201610278690.6A patent/CN105853430A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| BING-XIN ZHAO等: "Virosaines A and B,Two New Birdcage-Shaped Securinega Alkaloids with an Unprecedented Skeleton from Flueggea virosa", 《ORGANIC LETTERS》 * |
| 赵艳等: "一叶秋碱的临床新用途", 《中国临床医生》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104127421B (en) | The application in preparing anti-erythrocyte low property anemia medicine of O-(piperidyl) ethyl derivative of Cleistanone Cleistanone | |
| CN104288159B (en) | The application in preparing anti-erythrocyte low property anemia medicine of O-(piperazinyl) ethyl derivative of Cleistanone | |
| CN104147014B (en) | The application in preparing anti-erythrocyte low property anemia medicine of the diethylamine derivative of Cleistanone Cleistanone | |
| CN105250308A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells | |
| CN104800222A (en) | Application of O-(benzimidazolyl) ethyl derivative of cleistanone in preparing drug for preventing red blood cell hypoplastic anemia | |
| CN105078985A (en) | Composition 53083001030571 and application of composition 53083001030571 to drug for resisting low-hematocrit anemia | |
| CN104922123A (en) | Application of O-(diethylin) ethyl derivative of Daphmalenine A to preparation of drug for resisting red blood cell hypoplastic anemia | |
| CN105853430A (en) | Application of composition of piperazine and imidazole based derivatives of Virosaine A in preparation of drugs against red blood cell hypoplastic anemia | |
| CN106038551A (en) | Application of composition of Schiglautone A derivatives in preparation of low-erythrocyte anemia preventive drugs | |
| CN105287570A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells | |
| CN105935361A (en) | Application of composition of Virosaine A tetrahydropyrrole and morpholinyl derivatives in drugs for resisting low red blood cell anemia | |
| CN105250293A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells | |
| CN105193815A (en) | Composition and application thereof in drugs for preventing low-erythrocyte anemia | |
| CN105287525A (en) | Composition and application of composition in medicine for resisting low red blood cell type anemia | |
| CN105250258A (en) | Composition and application of composition in medicine for resistance of erythrocyte low anemia | |
| CN105998010A (en) | Application of composition of Salviskinone A derivatives in anti-low red blood cell anemia drugs | |
| CN104887667A (en) | Application of Daphmalenine A ramification to preparing medicine for resisting low red blood cell anemia | |
| CN105287455A (en) | Composition and application thereof to medicines resistant to anemia due to low red cells | |
| CN105343085A (en) | Composition and application thereof in low erythrocyte anemia resistant drugs | |
| CN105343083A (en) | Composition and application of composition in medicines for resisting low erythrocyte anemia | |
| CN106074479A (en) | The compositions of the derivant of Artalbic acid is used for preparing anti-erythrocyte low property anemia medicine | |
| CN105497038A (en) | Composition and application thereof to low-erythrocyte anemia resistant medicament | |
| CN106074528A (en) | The composition of Ah draw'sing Bick acid triazolyl and 1H tetrazole radical derivative is for preparing anti-erythrocyte low property anaemia medicine | |
| CN105616403A (en) | Composition and application thereof to low red blood cell anemia resisting medicine | |
| CN106420727A (en) | Application of composition of Artalbic acid derivatives in medicine for resisting red cell low type anemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160817 |